![Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer | Breast Cancer Research | Full Text Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-019-1235-8/MediaObjects/13058_2019_1235_Fig4_HTML.png)
Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer | Breast Cancer Research | Full Text
![POR | Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016 POR | Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016](https://www.por-journal.com/files/Articles/603937/pore-27-603937-HTML-r1/image_m/pore-27-603937-g002.jpg)
POR | Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016
![Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer | Breast Cancer Research | Full Text Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-019-1235-8/MediaObjects/13058_2019_1235_Fig5_HTML.png)
Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer | Breast Cancer Research | Full Text
![Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer | Breast Cancer Research | Full Text Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-019-1235-8/MediaObjects/13058_2019_1235_Fig3_HTML.png)
Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer | Breast Cancer Research | Full Text
![Sensors | Free Full-Text | Microfluidic Organ/Body-on-a-Chip Devices at the Convergence of Biology and Microengineering Sensors | Free Full-Text | Microfluidic Organ/Body-on-a-Chip Devices at the Convergence of Biology and Microengineering](https://www.mdpi.com/sensors/sensors-15-29848/article_deploy/html/images/sensors-15-29848-g001.png)
Sensors | Free Full-Text | Microfluidic Organ/Body-on-a-Chip Devices at the Convergence of Biology and Microengineering
![IJMS | Free Full-Text | Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA IJMS | Free Full-Text | Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA](https://www.mdpi.com/ijms/ijms-24-07235/article_deploy/html/images/ijms-24-07235-g001.png)
IJMS | Free Full-Text | Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
![Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma | BMC Cancer | Full Text Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-016-2677-3/MediaObjects/12885_2016_2677_Fig2_HTML.gif)
Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma | BMC Cancer | Full Text
![POR | Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016 POR | Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016](https://www.por-journal.com/files/Articles/603937/pore-27-603937-HTML-r1/image_m/pore-27-603937-g001.jpg)
POR | Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016
![Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma | BMC Cancer | Full Text Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-016-2677-3/MediaObjects/12885_2016_2677_Fig1_HTML.gif)
Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma | BMC Cancer | Full Text
![Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management | Acta Neuropathologica Communications | Full Text Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management | Acta Neuropathologica Communications | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40478-022-01362-3/MediaObjects/40478_2022_1362_Fig2_HTML.png)
Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management | Acta Neuropathologica Communications | Full Text
![POR | Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016 POR | Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016](https://www.por-journal.com/files/Articles/603937/pore-27-603937-HTML-r1/image_m/pore-27-603937-g004.jpg)